[MP-202417] Tarlatamab (SCLC)
Project no.:
MP-202417
Report type:
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of extensive-stage small cell lung cancer (ESSCLC)
Note:
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the NCPHP (National Centre for Public Health and Pharmacy) Hungary.
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| 2nd quarter, 2025 | |
| 3rd quarter, 2026 |